€445.15
Your prediction
Vertex Pharmaceuticals Inc. Stock
Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Vertex Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | -0.180% | 9.008% | 19.334% | 44.320% | 19.992% | 158.492% | 198.095% |
| Exact Sciences | -0.090% | -1.795% | -30.284% | -48.513% | -40.121% | -53.295% | -56.613% |
| Incyte Corp. | 0.220% | 1.398% | 6.807% | -7.066% | -5.428% | -21.618% | -25.181% |
| Regeneron Pharmaceuticals Inc. | 0.520% | 2.567% | 3.258% | 31.286% | 15.235% | 118.627% | 247.974% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Vertex Pharmaceuticals Inc (VRTX) has been growing consistently in the Biotechnology & Medical Research industry in recent years, as indicated by its financial statements. The company's financials, from its balance sheets to its income and cash flow statements, exhibit a strong growth in its assets, revenues, and profits.
Vertex has shown significant growth in total assets, as evidenced by a consistent increase from almost $11.75 billion in 2020 to over $18.15 billion in 2022. This growth highlights the company's strong financial position, enabling it to capitalize on investment opportunities and fuel further expansion.
The total revenue Vertex generated also increased from over $6.2 billion in 2020 to nearly $8.9 billion in 2022. The steady rise in sales is a positive sign for investors and points to the company's successful execution of its growth strategy.
Comments
News
Got $500? 3 Pharma Stocks to Buy and Hold Forever
A sum of $500 might not seem like much of an investment, but if you select the right pharmaceutical stocks -- and are patient enough to hold them forever -- history shows you'll have a very high
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Vertex Pharmaceuticals (NASDAQ: VRTX) is a fast-growing pharmaceutical company that investors have been bullish on for years. The business generates billions in revenue from cystic fibrosis drugs
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
As its shareholders already know, CRISPR Therapeutics (NASDAQ: CRSP) has quite a few opportunities on the table. Between its commercialized medicine, a pipeline that's packed with chances to mint